CCP
BIVV

Clough Capital Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Clough Capital Partners’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-108,600
Closed -$5.86M – 170
2017
Q4 		$5.86M Sell
108,600
-62,300
-36% -$3.41M 0.49% 60
2017
Q3 		$9.75M Sell
170,900
-25,300
-13% -$1.48M 0.65% 48
2017
Q2 		$11.8M Buy
+196,200
New +$11.2M 0.82% 41

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Clough Capital Partners's BIVV Position: Q1 2018 in Review

Clough Capital Partners sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 108,600 shares — an estimated $5.86M sold.

Clough Capital Partners first reported a position in BIVV in Q2 2017 and held it in 3 quarters. The position peaked at $11.8M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Clough Capital Partners reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Clough Capital Partners sold 108,600 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $5.86M.
  • Clough Capital Partners first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Clough Capital Partners's Bioverativ Inc. Common Stock position peaked at $11.8M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Clough Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.